Daunorubicin HCl

Name: Daunorubicin HCl
Brand: Selleck Chemicals
SKU: S3035
Rating: 5 (27 reviews)

For research use only. Not for use in humans.

Catalog No.S3035 Synonyms: Daunomycin HCl

27 publications

Molecular Weight(MW): 563.98

Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with K_i of 0.02 μM in a cell-free assay.

Selleck's Daunorubicin HCl has been cited by 27 publications

Nat Med, 2017, 23(2):250-255

PubMed: 27991919 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.224956

PubMed: 31624110 ( click the link to review the publication )

ACS Chem Biol, 2019, 14(3):348-355

PubMed: 30763062 ( click the link to review the publication )

J Lipid Res, 2019, 60(6):1078-1086

PubMed: 30962310 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2457-2468

PubMed: 31551253 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(6):4111-4117

PubMed: 30920135 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(3):579-586

PubMed: 30745844 ( click the link to review the publication )

Oncol Rep, 2019, 41(6):3179-3188

PubMed: 30942458 ( click the link to review the publication )

Leuk Lymphoma, 2019, 1-9

PubMed: 31526067 ( click the link to review the publication )

Oncotarget, 2019, 10(56):5755-5767

PubMed: 31645898 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5378

PubMed: 30568163 ( click the link to review the publication )

mSphere, 2018, 3(5)

PubMed: 30381352 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(7):1716-1726

PubMed: 29330206 ( click the link to review the publication )

Bioinformation, 2018, 587-593

PubMed: 31223218 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):22

PubMed: 28143565 ( click the link to review the publication )

Mol Cell Biochem, 2017, 434(1-2):25-32

PubMed: 28397012 ( click the link to review the publication )

Leuk Res, 2017, 63:41-46

PubMed: 29100024 ( click the link to review the publication )

Leuk Res, 2017, 56:36-43

PubMed: 28171800 ( click the link to review the publication )

Sci Transl Med, 2016, 8(339):339ra69

PubMed: 27194727 ( click the link to review the publication )

Toxicol Rep, 2016, 3:430-438

PubMed: 28959565 ( click the link to review the publication )

Toxicology Reports, 2016, 10.1016/j.toxrep.2016.03.008

PubMed: ( click the link to review the publication )

Arch Toxicol, 2016, 90(11):2763-2777

PubMed: 26537877 ( click the link to review the publication )

J Transl Med, 2016, 14(1):132

PubMed: 27176825 ( click the link to review the publication )

Leuk Res, 2015, 39(4):435-44

PubMed: 25659731 ( click the link to review the publication )
J Phys Chem B, 2013, 117(23):6859-67

PubMed: 23692060 ( click the link to review the publication )

J Phys Chem B, 2013, 117(23):6868-73

PubMed: 23692121 ( click the link to review the publication )

J Phys Chem B, 2013, 117(23):6868-73

PubMed: 23692121 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description

Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with K_i of 0.02 μM in a cell-free assay.

Targets

DNA synthesis ^[1]
(Cell-free assay)

20 nM(Ki)

In vitro

At drug concentrations that reflect the peak plasma concentration after Daunorubicin administration, the primary mechanism is likely to be through interaction with topoisomerase II, which may be a primary triggering event for growth arrest and/or cell killing through a signalling pathway leading to apoptosis, at least in leukemic cells and thymocytes. The quinone structure permits daunorubicin to act as electron acceptors in reactions mediated by oxoreductive enzymes including cytochrome P450 reductase, NADH dehydrogenase, and xanthine oxidase. At Daunorubicin concentrations exceeding approximately 2–4 μM, free radical mediated toxicity and DNA cross-linking may become evident. Daunorubicin inhibits both DNA and RNA syntheses in HeLa cells over a concentration range of 0.2 through 2 μM. Daunorubicin inhibits both DNA syntheses in Ehrlich ascites tumor cells over a concentration range of 4 μM. Daunorubic triggers apoptosis at concentrations of 0.5 and 1 μM in either HL-60 or U-937 human leukemic cells. ^[1] Daunorubicin stimulates ceramide elevation and apoptosis in P388 and U937 cells through de novo synthesis via activation of the enzyme ceramide synthase. ^[2] Daunorubicin dose-dependently increases the phosphatidylserine exposure and consequent procoagulant activity of human umbilical vein endothelial cells. Daunorubicin (0.2 mM) significantly enhances the release of endothelial microparticles which are highly procoagulant in human umbilical vein endothelial cells. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
P388 leukemia cell line	MX;DfZRwfG:6aXRCpIF{e2G7			MW\Dc41xd3WwZDD3ZZMh\X[jbIXheIVlKG[xcjDjfZRwfG:6aXPpeJkh[WejaX7zeEBROzh6IHzleYtmdWmjIHPlcIwhdGmwZTygTWM2OD1\|IH7N	M1jIUFExPDd7Mkm3
HL60 cells	MnLNSpVv[3Srb36gZZN{[Xl?			MlzrTY4hfmm2cn:gbY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RicILvcIln\XKjdHnvckBw\iCKTE[wJINmdGy\|LDDJR\|UxRTBwMEC1JO69VQ>?	NWrCdHFNOTJ6N{e1PVM>
human epidermoid carcinoma cell line KB-3-1	MYHDfZRwfG:6aXRCpIF{e2G7			MXvJckB3cXS{bzDjfZRwfG:6aXOgZYN1cX[rdImge4F{KGW4YXz1ZZRm\CC3c3nu[{B1cGViaIXtZY4h\XCrZHXycY9q\CClYYLjbY5wdWFiY3XscEBtcW6nIFvCMVMuOSxiSVO1NF04KG6P	MkG4NVI1PDN5NkO=
human K562 cells	M1zITGN6fG:2b4jpZ:Kh[XO\|YYm=		MmTOO\|IhcA>?	NHjF[HREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFczKGi{czDifUBZXFRiYYPzZZktKEeLNUC9O{41KG6P	NUOw[\|F[OjB3OUG2O\|g>
Dx5 w/PSC cell lines	MoDaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MmfoWIhmKGOxbYDveY5lKHejczDleoFtfWG2ZXSg[o9zKHSqZTDndo94fGhiaX7obYJqfGmxbjDv[kBFgDVidz;QV2Mh[2WubDDsbY5meyC3c3nu[{BOXFRiYYPzZZktKEmFNUC9NVQhdk1?	NYq1[FdxOTB4OUi0OFk>
MDA MB 361(mammary carcinoma cell line)	NWSyZ2NYS3m2b4TvfIlkyqCjc4PhfS=>			MWXUbIUh[2:vcH;1coQhf2G\|IITld5Rm\CCob4KgbY51emGlZXzseYxieiCleYTveI95cWOrdImgZYdicW6\|dDDNSGEhVUJiM{[xLI1idW2jcomgZ4Fz[2mwb33hJINmdGxibHnu[Ukh\XiycnXzd4lv\yCOYXPaJEhj\XSjLXfhcIFkfG:\|aXThd4UqNCCLQ{WwQVE4KG6P	MWKxNFM6PTR7MB?=
human MDA-MB-231 cells	M{jzdGN6fG:2b4jpZ:Kh[XO\|YYm=		M4TEWFczKGh?	NIjvbWpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwQVAvODJizszN	NETkeY0yQTl4OEK1PC=>
MES-SA uterine tumor cell lines	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NYfOU4g4XGinIHPvcZBwfW6mIIfhd{BmfmGudXH0[YQh\m:{IITo[UBoem:5dHigbY5pcWKrdHnvckBw\iCPRWOtV2EhfXSncnnu[UB1fW2xcjDj[YxtKGyrbnXzJJV{cW6pIF3UWEBie3OjeTygTWM2OD1yLkCyNUDPxE1?	NULKfZd{OTB4OUi0OFk>
murine L1210 leukemia cells	NUjHN5dxTnWwY4Tpc44h[XO\|YYm=			MW\Jcohq[mm2b4L5JIFkfGm4aYT5JJdieyCvZXHzeZJm\CCjZ3HpcpN1KG23cnnu[UBNOTJzMDDs[ZVs\W2rYTDj[YxteyxiSVO1NF0{OCCwTR?=	MofoPVc{OzR6Mx?=
HL60 cells	MYLGeY5kfGmxbjDhd5NigQ>?			NF32bJRKdiC4aYTyc{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlv\HWlZTDhdI9xfG:\|aYOgbY4hUEx4MDDj[YxteyxiQVO1NF0xNjB2IN88US=>	M2nZdFEzQDd5NUmz
CCRF-CEM (human lymphoblastic leukemic) cells	NIfmd5JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NEPMWmpKdiC4aYTyc{Boem:5dHigbY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JGNEWkZvQ1XNJEhpfW2jbjDsfY1xcG:kbHHzeIlkKGyndXvlcYlkMSClZXzsd{whUUR3ME2wMlA1KM7:TR?=	NGjyVIo3QTVzMES5
mouse NIH/3T3 cells	NI\UTGhEgXSxdH;4bYPDqGG\|c3H5		MlGwO\|IhcA>?	NWDReIpoUW62cnnud4lkKGO7dH;0c5hq[2m2eTDh[4FqdnO2IIfpcIQhfHmyZTDtc5V{\SCQSVivN3Q{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;MD6wOFQh\|ryP	NV\sVWl1OTh7NUSwOFA>
human prostate cancer HTB-81 cells	M1zuemN6fG:2b4jpZ:Kh[XO\|YYm=			NEfEephEgXSxdH;4bYNqfHlidHjheEBk[XW\|ZXSgZUA2OCVicnXkeYN1cW:wIHnuJIFje2:{YnHuZ4Uh[XRiNEmwJI5uKGmwIHj1cYFvKHC{b4P0ZZRmKGOjbnPldkBJXEJvOEGgZ4VtdHNidYPpcochVVSVIHHzd4F6NCCHQ{WwQVAvODV6IN88US=>	MoH4NVExOjB{OEW=
human breast carcinoma line cells	NX\RTXRKTnWwY4Tpc44h[XO\|YYm=			NWr3epk6[2:vcH;1coQhf2G\|IITld5Rm\CCrbjD2bZRzdyCob4KgbY5pcWKrdHnvckBi[3Srdnn0fUBi\2GrboP0JIEhe2Wwc3n0bZZmKGi3bXHuJIJz\WG\|dDDjZZJkcW6xbXGgcIlv\SClZXzsd{whUUN3ME2wMlA3KM7:TR?=	NIHiUXU6OjV6M{Wx
MCF-7 cells	MWrDfZRwfG:6aXRCpIF{e2G7			M{S4RWNwdXCxdX7kJJdieyC2ZYP0[YQh\m:{IHn0d{B1d3irY3n0fUBi\2GrboP0JIh2dWGwIHLy[YF{fCClYX7j[ZIh[2WubIOoUWNHNTdrLDDJR\|UxRTBwME[g{txO	NWnOXmNZQTV2OEiyNC=>
human HT-29 cells	MX7DfZRwfG:6aXRCpIF{e2G7		MXS3NkBp	NFK0cmFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygS2k2OD1yLkC3JO69VQ>?	MoD3NVk6Pjh{NUi=
human uterine sarcoma cell line MES-SA	M13KNWN6fG:2b4jpZ:Kh[XO\|YYm=			NWfHWYRGUW5idnn0do8h[3m2b4TvfIlkKGGldHn2bZR6KHejczDleoFtfWG2ZXSgeZNqdmdidHjlJIh2dWGwIIX0[ZJqdmVic3HyZ49u[SClZXzsJIxqdmViTVXTMXNCNCCLQ{WwQVAvODdizszN	MUmxNlQ1Ozd4Mx?=
human MRC5 cells	MXLQdo9tcW[ncnH0bY9vKGG\|c3H5			M4XuRmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTWLDOUBk\WyuczDifUBZXFRiYYPzZZktKEmFNUC9NE4xPzhizszN	Mle0NlU1Pjd{OUG=
MDA435/LCC6 cells	NV75S5duWHKxbHnm[ZJifGmxbjDhd5NigQ>?			NXjvTWRJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBOTEF2M{WvUGNEPiClZXzsd{BjgSCHTFnTRUwhUUN3ME2wMlA4QSEQvF2=	MVmxO\|E2PDVyNR?=
human A549 cells	Mn;YR5l1d3SxeHnjxsBie3OjeR?=			NXfqZWFvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygS2k2OD1yLkC4JO69VQ>?	NGHj[nYyQTl4OEK1PC=>
Jurkat T lymphocytes	NVLpSGpqS3m2b4TvfIlkyqCjc4PhfS=>			NV;LSmdoS3m2b4TvfIlkcXS7IHHnZYlve3RiSoXyb4F1KFRibIntdIhw[3m2ZYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODh{NjFOwG0>	M2rOSlE3OzZ4NkCy
human DU145 cells	NGj6dodRem:uaX\ldoF1cW:wIHHzd4F6		MkjNO\|IhcA>?	M1jxS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRGWxOFUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkC5JO69VQ>?	NWDSXG14OjJ{NkCxOlY>
human MDA-MB-231 cells	NFLWS3hRem:uaX\ldoF1cW:wIHHzd4F6			MnS3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGK7IGjUWEBie3OjeTygTWM2OD1yLkC5NUDPxE1?	NWLUfWEyOjV2NkeyPVE>
human H1299 cells	NEOxWnJRem:uaX\ldoF1cW:wIHHzd4F6			NUHsXFBLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDINVI6QSClZXzsd{BjgSC[VGSgZZN{[XluIFnDOVA:OC5yOU[g{txO	MVqyOVQ3PzJ7MR?=
human HL60 cells	Mnr1R5l1d3SxeHnjxsBie3OjeR?=		NHmyc5g1QCCq	NXzQUmtwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nlidIL5dIFvKGKudXWgd5RicW6rbnetZoF{\WRiaHXtc4N6fG:vZYTybYMh[W6jbInzbZMtKEeLNUC9NE4yKM7:TR?=	NGfodYgzPTh5NEOzOS=>
human LNCAP cells	NELmemlEgXSxdH;4bYPDqGG\|c3H5		MofmOEBl[Xm\|	M1Tnb2N6fG:\|dHH0bYMh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{Bi\nSncjC0JIRigXNiYomgUXRVKGG\|c3H5MEBKSzVyPUCuNUDPxE1?	NF7xPHMzOjR6MES5OS=>
NCI-H69 cell line	M{XDTXBzd2yrZnXyZZRqd25iYYPzZZk>			NEDIWWFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIRzfWdic3Xud4l1cX[nIF7DTU1JPjliY3XscEBtcW6nIHL5JGFt[W2jcjDCcJVmKGG\|c3H5MEBKSzVyPUCuNUDPxE1?	M3O0XFE4Ojh4M{mz
human A2780 cells	MXrDfZRwfG:6aXRCpIF{e2G7		MWG3NkBp	MojHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlEyPzR7IN88US=>	NHfaRpMyPzh7MEC5OC=>
human HT-29 cells	MXnQdo9tcW[ncnH0bY9vKGG\|c3H5		M{\sSVk3KGh?	NXrYRmllSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUCuNVM{KM7:TR?=	MViyO\|c5PDR7
B16 mouse melanoma cells	NFXJdIVEgXSxdH;4bYPDqGG\|c3H5			NYi2cGFJS3m2b4TvfIlkcXS7IIToZZQh[2G3c3XkJIEhPTBnIILl[JVkfGmxbjDpckBi[nOxcnLhcoNmKGG2IES5NEBvdSCrbjDCNVYhdW:3c3WgcYVt[W6xbXGgZ4VtdHNidYPpcochVVSVIHHzd4F6NCCHQ{WwQVAvOTZizszN	NIfqUWYyOTB{MEK4OS=>
human SKMES1 cells	M3f5XXBzd2yrZnXyZZRqd25iYYPzZZk>		NXPYR3NVPzJiaB?=	MlmxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVS13FV\|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkG3JO69VQ>?	NGHObmYzOjJ4MEG2Oi=>
human fibroblast (NHF) cells	M2HJOWN6fG:2b4jpZ:Kh[XO\|YYm=			NWT2WGdCS3m2b4TvfIlkcXS7IIToZZQh[2G3c3XkJIEhPTBnIILl[JVkfGmxbjDpckBi[nOxcnLhcoNmKGG2IES5NEBvdSCrbjDuc5Ju[WxiaIXtZY4h\mmkcn;icIF{fCBqTljGLUBk\WyuczD1d4lv\yCPVGOgZZN{[XluIFXDOVA:OC5{MjFOwG0>	MkH6NVExOjB{OEW=
mouse L1210 cells	NUixSXZ3TnWwY4Tpc44h[XO\|YYm=			NXzk[YZnUW6qaXLpeIlwdiCxZjDSUmEhe3mwdHjld4l{KGmwIH3veZNmKExzMkGwJINmdGy\|LDDFSFUxRTBwMkOg{txO	NGPIbWE3QTB7OUm=
human NCI-H460 cells	MYTGeY5kfGmxbjDhd5NigQ>?			NULOcWVbSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KNE[wJINmdGy\|LDDJR\|UxRTBwM{ig{txO	MYmyNVU6QTByMB?=
human MCF7 cells	NUnYVJFHS3m2b4TvfIlkyqCjc4PhfS=>		MWC0JIRigXN?	NVzSPXdyS3m2b4P0ZZRq[yCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlQh\|ryP	M1G5VlIzPDhyNEm1
human SF268 cells	M1PZO2Z2dmO2aX;uJIF{e2G7			MWXBcpRq[2GwY3XyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1[yOlgh[2WubIOsJGlEPTB;MD62JO69VQ>?	NH24PYkzOTV7OUCwNC=>
human KB cells	MVnDfZRwfG:6aXRCpIF{e2G7		NEfCSos1QCCq	MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTBwNkSg{txO	M1;T[\|IxOzZ\|MUSy
human HepG2 cells	MljLR5l1d3SxeHnjxsBie3OjeR?=		MlLwNlQhcA>?	MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRUKGG\|c3H5MEBKSzVyPUCuO{DPxE1?	MnizNlExQTRyNEm=
mouse L5178Y cells	MY\DfZRwfG:6aXRCpIF{e2G7		M4TabFI1KGh?	M2P3N2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGw2OTd6WTDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvPzJizszN	NYP3UnJIOjNzOUm0O\|k>
human MCF7 cells	M17EbWN6fG:2b4jpZ:Kh[XO\|YYm=		MWq3NkBp	MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDYWHQh[XO\|YYmsJGdKPTB;MD64OkDPxE1?	Mli4NlA2QTF4N{i=
human MRC5 cells	NFjC[mFRem:uaX\ldoF1cW:wIHHzd4F6			M2LScGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTWLDOUBk\WyuczygTWM2OD1yLki4JO69VQ>?	M3z6XVIyPTl7MECw
MDA435/LCC6 cells	MULQdo9tcW[ncnH0bY9vKGG\|c3H5			NWLZZXZrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBufWy2aXTyeYchemW\|aYP0ZY51KE2GQUSzOU9NS0N4IHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvQTd5IN88US=>	MWexO\|E2PDVyNR?=
mouse NIH/3T3 cells	M2O4XGN6fG:2b4jpZ:Kh[XO\|YYm=		MVO3NkBp	M161WWlvfHKrboPpZ{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBPUUhxM2SzJINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKE2GUkGgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zLkCxJO69VQ>?	MmT2NVg6PTRyNEC=
human Detroit 551 cells	MUjDfZRwfG:6aXRCpIF{e2G7		NXHNVHZ5PzJiaB?=	MXnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDE[ZRzd2m2IEW1NUBk\WyuczDh[pRmeiB5MjDodpMh[nliWGTUJIF{e2G7LDDHTVUxRTFwN{eg{txO	NYTESGFyOjB3OUG2O\|g>
mouse DA-3 cells	MlXZR5l1d3SxeHnjxsBie3OjeR?=		MUCyOEBp	MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDERU0{KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDYWHQh[XO\|YYmsJGlEPTB;MT65JO69VQ>?	NHXuPY0zPDlyME[2PC=>
african green monkey Vero cells	M2XRRWN6fG:2b4jpZ:Kh[XO\|YYm=		NU\KeGt{OyCmYYnz	NXPSOW5DS3m2b4TvfIlkcXS7IHHnZYlve3RiYX\ybYNidiCpcnXlckBud26tZYmgWoVzdyClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRUKGG\|c3H5MEBKSzVyPUKuOUDPxE1?	M13CNVIyODl2MES5
Dx5 cell lines	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NUXIRWpyXGinIHPvcZBwfW6mIIfhd{BmfmGudXH0[YQh\m:{IITo[UBoem:5dHigbY5pcWKrdHnvckBw\iCGeEWgZ4VtdCCuaX7ld{B2e2mwZzDNWHQh[XO\|YYmsJIlkPTB;MjFOwG0>	MUWxNFY6QDR2OR?=
human HeLa3 cell line	MVXDfZRwfG:6aXRCpIF{e2G7			NX3PXJIyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYUOgZ4VtdCCuaX7lJIJ6KE2WVDDhd5NigSxiSVO1NF0zNjl4IN88US=>	NEfBdFAyPjl2MkCzOy=>
mouse L5178Y cells	NF30c4xEgXSxdH;4bYPDqGG\|c3H5		MXKyOEBp	NIPsVXlEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBNPTF5OGmgZ4VtdHNiZYjwdoV{e2mwZzDwMYdxKGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEmFNUC9O{44OyEQvF2=	M2jCTFI{OTl7NEe5
human CRL7761 cells	NFThcldEgXSxdH;4bYPDqGG\|c3H5		MWizJIRigXN?	MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDVmw4PzZzIHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFNiYYPzZZktKEmFNUC9NVAvPSEQvF2=	NV7sOllYOjFyOUSwOFk>
human A2780/ADR cells	NUCyO4Z5S3m2b4TvfIlkyqCjc4PhfS=>		NWDHT41KPzJiaB?=	MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OC:DRGKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yQC54MkC5JO69VQ>?	M1fRc\|E4QDlyMEm0
human SKOV3 cells	MUPDfZRwfG:6aXRCpIF{e2G7		M1jTflI1KGh?	MmrkR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JHhVXCCjc4PhfUwhUUN3ME2yNE43KM7:TR?=	M1L2OFI1QTByNk[4
human ES2 cells	NXqwTpZ2S3m2b4TvfIlkyqCjc4PhfS=>		NXjiN3lrOjRiaB?=	NH;SOopEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBGWzJiY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JHhVXCCjc4PhfUwhUUN3ME2yOU42KM7:TR?=	MlroNlQ6ODB4Nki=
CEM cells	NYLWT41NS3m2b4TvfIlkyqCjc4PhfS=>		NIGyVXc4OiCq	MkLHR5l1d3SxeHnjbZR6KGGpYXnud5QhS0WPIHPlcIx{KGGodHXyJFczKGi{cx?=	MoG5NVc3ODh\|OU[=
HOS cells	M4\Y[GN6fG:2b4jpZ:Kh[XO\|YYm=		MoWyO\|IhcA>?	NI[4RllEgXSxdH;4bYNqfHliYXfhbY5{fCCKT2OgZ4VtdHNiYX\0[ZIhPzJiaILz	MUixO\|YxQDN7Nh?=
mouse DA-3 cells	NFuzPWtEgXSxdH;4bYPDqGG\|c3H5	NFG2U5EzOCEQvF2=	MYG2NEBucW6\|	NYDsc4NNS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhTEFvMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZZQhOjBidV2gZYZ1\XJiNkCgcYlveyCkeTDYWHQh[XO\|YYm=	MlG1NlQ6ODB4Nki=
human G361 cells	MmDmR5l1d3SxeHnjxsBie3OjeR?=		M{nHdlczKGh?	M4HxbGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGc{PjFiY3XscJMh[W[2ZYKgO\|IhcHK\|	MV2xO\|YxQDN7Nh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-Chk1 / Chk1 / p-ATR / ATR ; PubMed: 26727128 PLoS One After Caco-2 cells were treated with or without 1 μ M daunorubicin, whole cell extracts were collected at 1, 3, 6, 12, 24, and 48 h and immunoblotted for Chk1, p-Chk1, ATR, and p-ATR. β-actin served as the loading control.	26727128
Immunofluorescence	p-Chk1; PubMed: 26727128 PLoS One Caco-2 cells were treated with or without 1 μ M daunorubicin for 48 h, and then fixed and stained with anti-p-Chk1 antibody and DAPI. Images were collected under a fluorescence microscope. Scale bar = 10 μm.	26727128
Growth inhibition assay	Cell viability; PubMed: 30745844 Int J Biol Sci (A) Viability of AML cell lines under different concentrations of Dnr according to the CCK-8 assay. (B) IC50 of AML cell lines calculated according to the result of the CCK-8 assay.	30745844

Protocol

References

[4] Tardi P, et al. Leuk Res, 2009, 33(1), 129-139.

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (177.31 mM)
	Water	100 mg/mL (177.31 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Daunorubicin HCl SDF

Molecular Weight	563.98
Formula	C₂₇H₂₉NO₁₀ . HCl
CAS No.	23541-50-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	Daunomycin HCl
Smiles	Cl.COC1=C2C(=O)C3=C(C(=C4CC(O)(CC(OC5CC(N)C(O)C(C)O5)C4=C3O)C(C)=O)O)C(=O)C2=CC=C1

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03878927	Recruiting	Drug: CPX-351\|Drug: Gemtuzumab Ozogamicin	Acute Myeloid Leukemia	Weill Medical College of Cornell University\|Jazz Pharmaceuticals\|Pfizer	August 23 2019	Phase 1
NCT03896269	Recruiting	Drug: Liposome-encapsulated Daunorubicin-Cytarabine	Blasts 10-19 Percent of Bone Marrow Nucleated Cells\|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells\|High Risk Chronic Myelomonocytic Leukemia\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent High Risk Myelodysplastic Syndrome\|Refractory Chronic Myelomonocytic Leukemia\|Refractory High Risk Myelodysplastic Syndrome	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	May 14 2019	Phase 1
NCT02914977	Active not recruiting	Drug: Daunorubicin	Acute Lymphocytic Leukemia\|Acute Myeloid Leukemia	Tara Lin\|University of Kansas Medical Center	November 2016	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Blasticidin S HCl ^New

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
Doxorubicin (Adriamycin) HCl

Doxorubicin (Adriamycin) HCl is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis in tumor cells.
Etoposide

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Camptothecin

Camptothecin is a specific inhibitor of DNA topoisomerase I (Topo I) with IC50 of 0.68 μM in a cell-free assay. Phase 2.
SN-38

SN-38 is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks.
Topotecan HCl

Topotecan HCl is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively.

Features:Topotecan is a water-soluble derivative of camptothecin.
Idarubicin HCl

Idarubicin HCl is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells with IC50 of 3.3 ng/mL in a cell-free assay.

Features:Idarubicin is a substrate for CYP450 2D6 and 2C9.

Choose Your Country or Region

By Signaling Pathways

By product type

Daunorubicin HCl